Carlos E Durán, Judit Riera-Arnau, Shahab Abtahi, Romin Pajouheshnia, Vjola Hoxhaj, Magdalena Gamba, Ema Alsina, Mar Martin-Perez, Patricia Garcia-Poza, Ana Llorente-Garcia, Diana Gonzalez-Bermejo, Luisa Ibánez, Mònica Sabaté, Xavier Vidal, Elena Ballarín, Gabriel Sanfélix-Gimeno, Clara Rodríguez-Bernal, Salvador Peiró, Aníbal García-Sempere, Francisco Sanchez-Saez, Valentina Ientile, Ylenia Ingrasciotta, Claudio Guarneri, Matilde Tanaglia, Michele Tari, Ron Herings, Eline Houben, Karin Swart-Polinder, Emily Holthuis, Consuelo Huerta, Rosa Gini, Giuseppe Roberto, Claudia Bartolini, Olga Paoletti, Giorgio Limoncella, Anna Girardi, Giulia Hyeraci, Morten Andersen, Sarah Brøgger Kristiansen, Christine Erikstrup Hallgreen, Olaf Klungel, Miriam Sturkenboom
Background: In March 2018, the European pregnancy prevention programme for oral retinoids was updated as part of risk minimisation measures (RMM), emphasising their contraindication in pregnant women. Objective: To measure the impact of the 2018 revision of the RMMs in Europe by assessing the utilisation patterns of isotretinoin, alitretinoin and acitretin, contraceptive measures, pregnancy testing, discontinuation, and pregnancy occurrence concomitantly with a retinoid prescription. Methods: An interrupted time series (ITS) analysis to compare level and trend changes after the risk minimisation measures implementation was conducted on a cohort of females of childbearing age (12-55 years of age) from January 2010 to December 2020, derived from six electronic health data sources in four countries: Denmark, Netherlands, Spain, and Italy...
2023: Frontiers in Pharmacology